We found that patients with Child-Pugh B liver disease harbored more circulating suppressive CD14<sup>+</sup> monocytes at baseline compared with those with Child-Pugh A disease.<h4>Conclusions</h4>Although combination sorafenib and nivolumab demonstrated acceptable safety at the MTD in both Child-Pugh subgroups, the objective response rate was below the prespecified threshold to be declared worthy of further exploration. This evidence concerns the gene CD14 and liver disorder.